Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Short-term intravenous citalopram augmentation in partial/nonresponders with major depression: a randomized placebo-controlled study
Approximately 30–45 % of patients with major depressive episode ( MDE ) do not fully respond to st and ard recommended treatments and further strategies of intervention , including pharmacological augmentation , have been proposed for these patients . This study was aim ed to evaluate the efficacy of short-term , low-dose ( 10 mg/day ) intravenous ( i.v . ) citalopram augmentation versus placebo in a sample of patients with MDE and partial or no response to selective serotonin reuptake inhibitors ( SSRIs ) . Thirty-six patients with a Diagnostic and Statistical Manual for Mental Disorders , 4th edition , text revision criteria MDE and partial or no response to oral SSRIs were selected and r and omly assigned to citalopram ( n=18 ) or to placebo ( n=18 ) i.v . augmentation . The augmentation regimen lasted 5 consecutive days during which the patients were maintained on their current treatment with oral SSRIs . Analyses of variance with repeated measures on Hamilton Depression Rating Scale and Montgomery – Asberg Depression Rating Scale total scores , administered daily with blind-raters conditions , were done . With regard to the Hamilton Depression Rating Scale total scores , a significant time effect ( F=42.02 , P<0.0001 ) and timextreatment effect ( F=21.17 , P<0.0001 ) were found in favor of citalopram . Similar results were obtained from the analysis on Montgomery – Asberg Depression Rating Scale total scores : time effect ( F=50.07 , P<0.0001 ) , timextreatment effect ( F=19.91 , P<0.0001 ) , and treatment effect ( F=4.07 , P=0.05 ) . Even though referred to a small sample , the present findings seem to suggest that short-term , low-dose , i.v . citalopram augmentation may be effective in depressed patients with partial or no response to oral SSRIs . Further controlled studies performed with double-blind conditions are warranted to confirm the present results
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .